Protagonist Therapeutics (PTGX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Julian Harrison from BTIG maintained a Buy rating on the stock and has a $73.00 price target.
Julian Harrison has given his Buy rating due to a combination of factors surrounding Protagonist Therapeutics. The positive results from the VERIFY trial, which met all endpoints including the key secondary endpoint of phlebotomy rate, have paved the way for a New Drug Application (NDA) filing expected in the fourth quarter of 2025. These results also make rusfertide the first treatment to demonstrate statistically significant benefits on symptoms, potentially offering a unique position in payor discussions.
Additionally, the financial prospects for Protagonist Therapeutics are promising, with a $25 million milestone payment triggered by the VERIFY results and the potential for further significant payments and royalties if they opt out of their profit-sharing agreement with Takeda. The commercial opportunity for rusfertide is substantial, with an estimated $1 billion to $2 billion peak sales potential in polycythemia vera (PV), supported by the treatment’s compatibility with existing regimens and its ability to improve patient-related outcomes. These factors contribute to a favorable outlook for Protagonist Therapeutics, justifying the Buy rating.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $58.00 price target.